Theravance director receives new share and option grants
Theravance Biopharma director Laurie Smaldone Alsup received new equity compensation in the form of shares and options.
Rhea-AI Filing Summary
Theravance Biopharma director Laurie Smaldone Alsup received new equity compensation in the form of shares and options. On 2026-06-12, she was granted 6,009 Ordinary Shares at no cost, increasing her direct holdings to 80,989 shares.
On the same date, she was also granted a Share Option covering 13,398 Ordinary Shares at an exercise price of $16.6400 per share, expiring on 2036-06-11. According to the vesting terms, 1/12 of the option vests after each month of continuous service following the grant date, with any remaining unvested portion vesting on the date of the next annual shareholder meeting, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 19,407 shares
Grant/Award
2 txns
Insider
Smaldone Alsup Laurie
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option (Right to Buy) | 13,398 | $0.00 | $0.00 |
| Grant/Award | Ordinary Shares | 6,009 | $0.00 | $0.00 |
Holdings After Transaction:
Share Option (Right to Buy) — 13,398 contracts (Direct);
Ordinary Shares — 80,989 shares (Direct)
Footnotes (1)
- F1. This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.
Key Figures
Shares granted: 6,009 Ordinary Shares
Shares held after grant: 80,989 Ordinary Shares
Option grant size: 13,398 shares
+2 more
5 metrics
Shares granted
6,009 Ordinary Shares
Grant to Laurie Smaldone Alsup on 2026-06-12
Shares held after grant
80,989 Ordinary Shares
Direct holdings following share award
Option grant size
13,398 shares
Share Option (Right to Buy) granted 2026-06-12
Option exercise price
$16.6400 per share
Exercise price for 13,398-share option
Option expiration
June 11, 2036
Expiration date of newly granted option
Key Terms
Share Option (Right to Buy), Ordinary Shares, grant/award acquisition, exercise price, +2 more
6 terms
grant/award acquisition financial
"Transaction classified as grant/award acquisition under code A"
exercise price financial
"Share Option has an exercise price of $16.6400 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"The option’s expiration date is June 11, 2036"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
continuous month of service financial
"Option vests 1/12 after each continuous month of service"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Laurie Smaldone Alsup receive from Theravance Biopharma (TBPH)?
Laurie Smaldone Alsup received 6,009 Ordinary Shares and a stock option for 13,398 Ordinary Shares. The option has an exercise price of $16.6400 per share and represents additional potential ownership if exercised in the future, subject to vesting conditions.
What are the vesting terms of Laurie Smaldone Alsup’s new Theravance Biopharma stock option?
The option vests as to 1/12 of the 13,398 underlying Ordinary Shares after each month of continuous service following the grant date. Any remaining unvested shares then vest on the date of the next annual shareholder meeting, provided she remains in continuous service.
Is Laurie Smaldone Alsup’s Form 4 transaction in TBPH a market purchase or a grant?
The Form 4 shows a grant or award, not a market purchase. She acquired 6,009 Ordinary Shares at a price of $0.0000 per share and a stock option for 13,398 shares as part of compensation, both classified as grant or award acquisitions.
What is the exercise price and expiration date of Laurie Smaldone Alsup’s TBPH stock option?
The granted Share Option allows purchase of 13,398 Ordinary Shares at an exercise price of $16.6400 per share. The option expires on June 11, 2036, giving a long-term window to exercise vested portions, subject to the stated vesting schedule and service conditions.
Does the Form 4 for TBPH indicate any stock sales by Laurie Smaldone Alsup?
The Form 4 indicates only acquisitions, not sales. It reports one grant of 6,009 Ordinary Shares and one grant of a stock option over 13,398 Ordinary Shares. The transaction summary shows acquire transactions only, with no sell or dispose entries reported.
AI-generated analysis. How Rhea-AI works. Not financial advice.
